Ghandor, A., Nafea, D., Helmy, M., Abdel Mohsen, E., Ellhakim, S. (2022). COMPARISON BETWEEN CALGB 8811 PROTOCOL AND DFCI PROTOCOL IN ALL PATIENTS REGARDING THE RATE OF INFECTION AND COMPLETE REMISSION. ALEXMED ePosters, 4(1), 24-25. doi: 10.21608/alexpo.2022.120548.1364
Ashraf Ghandor; Dalia Nafea; Mona Wagdy Helmy; Essam Abdel Mohsen; Soha Adel Ellhakim. "COMPARISON BETWEEN CALGB 8811 PROTOCOL AND DFCI PROTOCOL IN ALL PATIENTS REGARDING THE RATE OF INFECTION AND COMPLETE REMISSION". ALEXMED ePosters, 4, 1, 2022, 24-25. doi: 10.21608/alexpo.2022.120548.1364
Ghandor, A., Nafea, D., Helmy, M., Abdel Mohsen, E., Ellhakim, S. (2022). 'COMPARISON BETWEEN CALGB 8811 PROTOCOL AND DFCI PROTOCOL IN ALL PATIENTS REGARDING THE RATE OF INFECTION AND COMPLETE REMISSION', ALEXMED ePosters, 4(1), pp. 24-25. doi: 10.21608/alexpo.2022.120548.1364
Ghandor, A., Nafea, D., Helmy, M., Abdel Mohsen, E., Ellhakim, S. COMPARISON BETWEEN CALGB 8811 PROTOCOL AND DFCI PROTOCOL IN ALL PATIENTS REGARDING THE RATE OF INFECTION AND COMPLETE REMISSION. ALEXMED ePosters, 2022; 4(1): 24-25. doi: 10.21608/alexpo.2022.120548.1364
COMPARISON BETWEEN CALGB 8811 PROTOCOL AND DFCI PROTOCOL IN ALL PATIENTS REGARDING THE RATE OF INFECTION AND COMPLETE REMISSION
1Department of Internal Medicine (Hematology Unit) Faculty of Medicine, University of Alexandria, Egypt
2Department of Hematology, Alexandria University
3Department of Clinical and Chemical Pathology, Faculty of Medicine Alexandria University
4Hematology Unit At Elmaadi Military Hospital
5Departments of Internal Medicine (Hematology Unit) Faculty of Medicine, University of Alexandria, Egypt
Abstract
ALL is primarily a disease of childhood, with 75% of cases occurring in children under the age of 10 years at diagnosis. However, although ALL is rare in adults, there is an increasing incidence with age after the age of 40 years. Eighty – five percent of cases are of B– cell lineage and have an equal sex incidence; there is a male predominance for the 15% of T - cell ALL.1 The clinical presentation of ALL is nonspecific, and thus, patients may present with “B symptoms”, infection, easy bruising / bleeding, dyspnea, and fatigue.2 The diagnosis of ALL requires the presence of 20% or more lymphoblasts in the bonemarrow. Further assessment by flow cytometry, morphological studies, immunophenotyping, and cytogenetic testing is important. The primary goal of induction therapy is complete eradication of lymphoblasts from the blood, bone marrow, CNS and other extramedullary sites when initially involved. Complete remission (CR) is currently defined on a morphological basis of less than 5% blasts in the bone marrow in the presence of over allhaematological recovery (neutrophils > 1.0 × 109 /L, platelets > 100 × 109/L).3